Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at Leerink Swann upped their Q2 2017 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Thursday. Leerink Swann analyst P. Matteis now anticipates that the biopharmaceutical company will post earnings per share of ($1.15) for the quarter, up from their previous estimate of ($1.22). Leerink Swann currently has a “Market Perform” rating and a $67.00 target price on the stock. Leerink Swann also issued estimates for Alnylam Pharmaceuticals’ Q3 2017 earnings at ($1.11) EPS, Q4 2017 earnings at ($1.02) EPS, FY2017 earnings at ($4.53) EPS and FY2018 earnings at ($4.96) EPS.
A number of other research firms also recently commented on ALNY. Jefferies Group LLC reaffirmed a “buy” rating and set a $102.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 22nd. Chardan Capital reaffirmed a “buy” rating and set a $131.00 price objective (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $98.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, July 10th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, June 26th. Finally, Credit Suisse Group boosted their target price on Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a report on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $79.79.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/leerink-swann-weighs-in-on-alnylam-pharmaceuticals-inc-s-q2-2017-earnings-nasdaqalny-updated.html.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 81.44 on Monday. The stock’s market cap is $7.02 billion. The stock has a 50 day moving average of $81.11 and a 200-day moving average of $60.45. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $86.92.
A number of large investors have recently modified their holdings of ALNY. Dimensional Fund Advisors LP raised its stake in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $1,036,000. Teachers Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock valued at $2,755,000 after buying an additional 7,048 shares in the last quarter. Macquarie Group Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 1,614 shares in the last quarter. Finally, Peregrine Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 7.5% in the first quarter. Peregrine Capital Management LLC now owns 221,909 shares of the biopharmaceutical company’s stock valued at $11,723,000 after buying an additional 15,477 shares in the last quarter. 88.96% of the stock is currently owned by hedge funds and other institutional investors.
In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total value of $656,250.00. Following the sale, the vice president now directly owns 5,625 shares of the company’s stock, valued at $393,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total value of $825,000.00. Following the completion of the sale, the executive vice president now directly owns 21,297 shares in the company, valued at $1,597,275. The disclosure for this sale can be found here. Insiders sold 64,125 shares of company stock worth $4,325,000 over the last ninety days. 4.30% of the stock is owned by corporate insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.